 | • レポートコード：MRC2312MG07427 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のバイオ医薬品CDMOサービス市場規模と予測を収録しています。・世界のバイオ医薬品CDMOサービス市場：売上、2018年-2023年、2024年-2029年 ・世界のバイオ医薬品CDMOサービス市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のバイオ医薬品CDMOサービス市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「革新的医薬品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 バイオ医薬品CDMOサービスのグローバル主要企業は、KBI Biopharma、 INCOG BioPharma Services、 CordenPharma、 AGC Biologics、 Northway Biotech、 PlantForm Corp、 Lonza、 ADL Biopharma、 Catalent、 Future Fields、 Vetter Pharma、 Stelis、 Richter-Helm、 FUJIFILM Diosynth Biotechnologies、 Cambrex、 Pfizer CentreOne、 Samsung Biologicsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、バイオ医薬品CDMOサービスのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のバイオ医薬品CDMOサービス市場：タイプ別、2018年-2023年、2024年-2029年 世界のバイオ医薬品CDMOサービス市場：タイプ別市場シェア、2022年 ・革新的医薬品、上場特許医薬品、バイオシミラー等開発 世界のバイオ医薬品CDMOサービス市場：用途別、2018年-2023年、2024年-2029年 世界のバイオ医薬品CDMOサービス市場：用途別市場シェア、2022年 ・製薬会社、バイオ企業、その他 世界のバイオ医薬品CDMOサービス市場：地域・国別、2018年-2023年、2024年-2029年 世界のバイオ医薬品CDMOサービス市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるバイオ医薬品CDMOサービスのグローバル売上、2018年-2023年 ・主要企業におけるバイオ医薬品CDMOサービスのグローバル売上シェア、2022年 ・主要企業におけるバイオ医薬品CDMOサービスのグローバル販売量、2018年-2023年 ・主要企業におけるバイオ医薬品CDMOサービスのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 KBI Biopharma、 INCOG BioPharma Services、 CordenPharma、 AGC Biologics、 Northway Biotech、 PlantForm Corp、 Lonza、 ADL Biopharma、 Catalent、 Future Fields、 Vetter Pharma、 Stelis、 Richter-Helm、 FUJIFILM Diosynth Biotechnologies、 Cambrex、 Pfizer CentreOne、 Samsung Biologics ************************************************************* ・調査・分析レポートの概要 バイオ医薬品CDMOサービス市場の定義 市場セグメント 世界のバイオ医薬品CDMOサービス市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のバイオ医薬品CDMOサービス市場規模 世界のバイオ医薬品CDMOサービス市場規模：2022年 VS 2029年 世界のバイオ医薬品CDMOサービス市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのバイオ医薬品CDMOサービスの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のバイオ医薬品CDMOサービス製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：革新的医薬品、上場特許医薬品、バイオシミラー等開発 バイオ医薬品CDMOサービスのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：製薬会社、バイオ企業、その他 バイオ医薬品CDMOサービスの用途別グローバル売上・予測 ・地域別市場分析 地域別バイオ医薬品CDMOサービス市場規模 2022年と2029年 地域別バイオ医薬品CDMOサービス売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） KBI Biopharma、 INCOG BioPharma Services、 CordenPharma、 AGC Biologics、 Northway Biotech、 PlantForm Corp、 Lonza、 ADL Biopharma、 Catalent、 Future Fields、 Vetter Pharma、 Stelis、 Richter-Helm、 FUJIFILM Diosynth Biotechnologies、 Cambrex、 Pfizer CentreOne、 Samsung Biologics ... |
This research report provides a comprehensive analysis of the Biopharmaceutical CDMO Service market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Biopharmaceutical CDMO Service market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Biopharmaceutical CDMO Service, challenges faced by the industry, and potential opportunities for market players.
The global Biopharmaceutical CDMO Service market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Biopharmaceutical CDMO Service market presents opportunities for various stakeholders, including Pharmaceutical Company, Biotechnology Company. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Biopharmaceutical CDMO Service market. Additionally, the growing consumer demand present avenues for market expansion.
The global Biopharmaceutical CDMO Service market was valued at US$ 13810 million in 2022 and is projected to reach US$ 28990 million by 2029, at a CAGR of 10.8% during the forecast period.
Key Features:
The research report on the Biopharmaceutical CDMO Service market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Biopharmaceutical CDMO Service market.
Market Overview: The report provides a comprehensive overview of the Biopharmaceutical CDMO Service market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Develop Innovative Drugs, Listed Patented Drug), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Biopharmaceutical CDMO Service market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Biopharmaceutical CDMO Service market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Biopharmaceutical CDMO Service market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Biopharmaceutical CDMO Service market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Biopharmaceutical CDMO Service market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Biopharmaceutical CDMO Service market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Biopharmaceutical CDMO Service, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Biopharmaceutical CDMO Service market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Biopharmaceutical CDMO Service market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Develop Innovative Drugs
Listed Patented Drug
Biosimilars
Others
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Others
Global Biopharmaceutical CDMO Service Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
KBI Biopharma
INCOG BioPharma Services
CordenPharma
AGC Biologics
Northway Biotech
PlantForm Corp
Lonza
ADL Biopharma
Catalent
Future Fields
Vetter Pharma
Stelis
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Cambrex
Pfizer CentreOne
Samsung Biologics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biopharmaceutical CDMO Service, market overview.
Chapter 2: Global Biopharmaceutical CDMO Service market size in revenue.
Chapter 3: Detailed analysis of Biopharmaceutical CDMO Service company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biopharmaceutical CDMO Service in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Biopharmaceutical CDMO Service Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Biopharmaceutical CDMO Service Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Biopharmaceutical CDMO Service Overall Market Size
2.1 Global Biopharmaceutical CDMO Service Market Size: 2022 VS 2029
2.2 Global Biopharmaceutical CDMO Service Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Biopharmaceutical CDMO Service Players in Global Market
3.2 Top Global Biopharmaceutical CDMO Service Companies Ranked by Revenue
3.3 Global Biopharmaceutical CDMO Service Revenue by Companies
3.4 Top 3 and Top 5 Biopharmaceutical CDMO Service Companies in Global Market, by Revenue in 2022
3.5 Global Companies Biopharmaceutical CDMO Service Product Type
3.6 Tier 1, Tier 2 and Tier 3 Biopharmaceutical CDMO Service Players in Global Market
3.6.1 List of Global Tier 1 Biopharmaceutical CDMO Service Companies
3.6.2 List of Global Tier 2 and Tier 3 Biopharmaceutical CDMO Service Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Biopharmaceutical CDMO Service Market Size Markets, 2022 & 2029
4.1.2 Develop Innovative Drugs
4.1.3 Listed Patented Drug
4.1.4 Biosimilars
4.1.5 Others
4.2 By Type – Global Biopharmaceutical CDMO Service Revenue & Forecasts
4.2.1 By Type – Global Biopharmaceutical CDMO Service Revenue, 2018-2023
4.2.2 By Type – Global Biopharmaceutical CDMO Service Revenue, 2024-2029
4.2.3 By Type – Global Biopharmaceutical CDMO Service Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Biopharmaceutical CDMO Service Market Size, 2022 & 2029
5.1.2 Pharmaceutical Company
5.1.3 Biotechnology Company
5.1.4 Others
5.2 By Application – Global Biopharmaceutical CDMO Service Revenue & Forecasts
5.2.1 By Application – Global Biopharmaceutical CDMO Service Revenue, 2018-2023
5.2.2 By Application – Global Biopharmaceutical CDMO Service Revenue, 2024-2029
5.2.3 By Application – Global Biopharmaceutical CDMO Service Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Biopharmaceutical CDMO Service Market Size, 2022 & 2029
6.2 By Region – Global Biopharmaceutical CDMO Service Revenue & Forecasts
6.2.1 By Region – Global Biopharmaceutical CDMO Service Revenue, 2018-2023
6.2.2 By Region – Global Biopharmaceutical CDMO Service Revenue, 2024-2029
6.2.3 By Region – Global Biopharmaceutical CDMO Service Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Biopharmaceutical CDMO Service Revenue, 2018-2029
6.3.2 US Biopharmaceutical CDMO Service Market Size, 2018-2029
6.3.3 Canada Biopharmaceutical CDMO Service Market Size, 2018-2029
6.3.4 Mexico Biopharmaceutical CDMO Service Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Biopharmaceutical CDMO Service Revenue, 2018-2029
6.4.2 Germany Biopharmaceutical CDMO Service Market Size, 2018-2029
6.4.3 France Biopharmaceutical CDMO Service Market Size, 2018-2029
6.4.4 U.K. Biopharmaceutical CDMO Service Market Size, 2018-2029
6.4.5 Italy Biopharmaceutical CDMO Service Market Size, 2018-2029
6.4.6 Russia Biopharmaceutical CDMO Service Market Size, 2018-2029
6.4.7 Nordic Countries Biopharmaceutical CDMO Service Market Size, 2018-2029
6.4.8 Benelux Biopharmaceutical CDMO Service Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Biopharmaceutical CDMO Service Revenue, 2018-2029
6.5.2 China Biopharmaceutical CDMO Service Market Size, 2018-2029
6.5.3 Japan Biopharmaceutical CDMO Service Market Size, 2018-2029
6.5.4 South Korea Biopharmaceutical CDMO Service Market Size, 2018-2029
6.5.5 Southeast Asia Biopharmaceutical CDMO Service Market Size, 2018-2029
6.5.6 India Biopharmaceutical CDMO Service Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Biopharmaceutical CDMO Service Revenue, 2018-2029
6.6.2 Brazil Biopharmaceutical CDMO Service Market Size, 2018-2029
6.6.3 Argentina Biopharmaceutical CDMO Service Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Biopharmaceutical CDMO Service Revenue, 2018-2029
6.7.2 Turkey Biopharmaceutical CDMO Service Market Size, 2018-2029
6.7.3 Israel Biopharmaceutical CDMO Service Market Size, 2018-2029
6.7.4 Saudi Arabia Biopharmaceutical CDMO Service Market Size, 2018-2029
6.7.5 UAE Biopharmaceutical CDMO Service Market Size, 2018-2029
7 Biopharmaceutical CDMO Service Companies Profiles
7.1 KBI Biopharma
7.1.1 KBI Biopharma Company Summary
7.1.2 KBI Biopharma Business Overview
7.1.3 KBI Biopharma Biopharmaceutical CDMO Service Major Product Offerings
7.1.4 KBI Biopharma Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.1.5 KBI Biopharma Key News & Latest Developments
7.2 INCOG BioPharma Services
7.2.1 INCOG BioPharma Services Company Summary
7.2.2 INCOG BioPharma Services Business Overview
7.2.3 INCOG BioPharma Services Biopharmaceutical CDMO Service Major Product Offerings
7.2.4 INCOG BioPharma Services Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.2.5 INCOG BioPharma Services Key News & Latest Developments
7.3 CordenPharma
7.3.1 CordenPharma Company Summary
7.3.2 CordenPharma Business Overview
7.3.3 CordenPharma Biopharmaceutical CDMO Service Major Product Offerings
7.3.4 CordenPharma Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.3.5 CordenPharma Key News & Latest Developments
7.4 AGC Biologics
7.4.1 AGC Biologics Company Summary
7.4.2 AGC Biologics Business Overview
7.4.3 AGC Biologics Biopharmaceutical CDMO Service Major Product Offerings
7.4.4 AGC Biologics Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.4.5 AGC Biologics Key News & Latest Developments
7.5 Northway Biotech
7.5.1 Northway Biotech Company Summary
7.5.2 Northway Biotech Business Overview
7.5.3 Northway Biotech Biopharmaceutical CDMO Service Major Product Offerings
7.5.4 Northway Biotech Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.5.5 Northway Biotech Key News & Latest Developments
7.6 PlantForm Corp
7.6.1 PlantForm Corp Company Summary
7.6.2 PlantForm Corp Business Overview
7.6.3 PlantForm Corp Biopharmaceutical CDMO Service Major Product Offerings
7.6.4 PlantForm Corp Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.6.5 PlantForm Corp Key News & Latest Developments
7.7 Lonza
7.7.1 Lonza Company Summary
7.7.2 Lonza Business Overview
7.7.3 Lonza Biopharmaceutical CDMO Service Major Product Offerings
7.7.4 Lonza Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.7.5 Lonza Key News & Latest Developments
7.8 ADL Biopharma
7.8.1 ADL Biopharma Company Summary
7.8.2 ADL Biopharma Business Overview
7.8.3 ADL Biopharma Biopharmaceutical CDMO Service Major Product Offerings
7.8.4 ADL Biopharma Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.8.5 ADL Biopharma Key News & Latest Developments
7.9 Catalent
7.9.1 Catalent Company Summary
7.9.2 Catalent Business Overview
7.9.3 Catalent Biopharmaceutical CDMO Service Major Product Offerings
7.9.4 Catalent Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.9.5 Catalent Key News & Latest Developments
7.10 Future Fields
7.10.1 Future Fields Company Summary
7.10.2 Future Fields Business Overview
7.10.3 Future Fields Biopharmaceutical CDMO Service Major Product Offerings
7.10.4 Future Fields Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.10.5 Future Fields Key News & Latest Developments
7.11 Vetter Pharma
7.11.1 Vetter Pharma Company Summary
7.11.2 Vetter Pharma Business Overview
7.11.3 Vetter Pharma Biopharmaceutical CDMO Service Major Product Offerings
7.11.4 Vetter Pharma Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.11.5 Vetter Pharma Key News & Latest Developments
7.12 Stelis
7.12.1 Stelis Company Summary
7.12.2 Stelis Business Overview
7.12.3 Stelis Biopharmaceutical CDMO Service Major Product Offerings
7.12.4 Stelis Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.12.5 Stelis Key News & Latest Developments
7.13 Richter-Helm
7.13.1 Richter-Helm Company Summary
7.13.2 Richter-Helm Business Overview
7.13.3 Richter-Helm Biopharmaceutical CDMO Service Major Product Offerings
7.13.4 Richter-Helm Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.13.5 Richter-Helm Key News & Latest Developments
7.14 FUJIFILM Diosynth Biotechnologies
7.14.1 FUJIFILM Diosynth Biotechnologies Company Summary
7.14.2 FUJIFILM Diosynth Biotechnologies Business Overview
7.14.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Major Product Offerings
7.14.4 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.14.5 FUJIFILM Diosynth Biotechnologies Key News & Latest Developments
7.15 Cambrex
7.15.1 Cambrex Company Summary
7.15.2 Cambrex Business Overview
7.15.3 Cambrex Biopharmaceutical CDMO Service Major Product Offerings
7.15.4 Cambrex Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.15.5 Cambrex Key News & Latest Developments
7.16 Pfizer CentreOne
7.16.1 Pfizer CentreOne Company Summary
7.16.2 Pfizer CentreOne Business Overview
7.16.3 Pfizer CentreOne Biopharmaceutical CDMO Service Major Product Offerings
7.16.4 Pfizer CentreOne Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.16.5 Pfizer CentreOne Key News & Latest Developments
7.17 Samsung Biologics
7.17.1 Samsung Biologics Company Summary
7.17.2 Samsung Biologics Business Overview
7.17.3 Samsung Biologics Biopharmaceutical CDMO Service Major Product Offerings
7.17.4 Samsung Biologics Biopharmaceutical CDMO Service Revenue in Global Market (2018-2023)
7.17.5 Samsung Biologics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
